Birgit Schoeberl

4.7k total citations · 1 hit paper
44 papers, 3.3k citations indexed

About

Birgit Schoeberl is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Birgit Schoeberl has authored 44 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 21 papers in Oncology and 16 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Birgit Schoeberl's work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and Computational Drug Discovery Methods (9 papers). Birgit Schoeberl is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and Computational Drug Discovery Methods (9 papers). Birgit Schoeberl collaborates with scholars based in United States, Germany and Switzerland. Birgit Schoeberl's co-authors include Ulrik B. Nielsen, Ernst Dieter Gilles, Claudia Eichler-Jonsson, Gertraud Müller, Peter K. Sorger, Jonathan B. Fitzgerald, Mario Niepel, Brian D. Harms, Neeraj Kohli and Douglas A. Lauffenburger and has published in prestigious journals such as Nature Communications, Nature Biotechnology and Cancer Cell.

In The Last Decade

Birgit Schoeberl

41 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors

2002 726 citations Birgit Schoeberl et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Birgit Schoeberl United States	21	2.4k	1.1k	785	503	263	44	3.3k
Richard M. Neve United States	29	2.8k 1.2×	2.3k 2.1×	534 0.7×	175 0.3×	761 2.9×	53	4.7k
Mario Niepel United States	25	2.6k 1.1×	591 0.5×	107 0.1×	497 1.0×	277 1.1×	42	3.4k
John G. Moffat United States	20	1.9k 0.8×	809 0.7×	144 0.2×	461 0.9×	266 1.0×	37	2.8k
Richard G. Posner United States	27	1.3k 0.5×	383 0.3×	342 0.4×	158 0.3×	177 0.7×	57	2.1k
Rachel Karchin United States	41	4.1k 1.7×	899 0.8×	254 0.3×	244 0.5×	1.6k 6.3×	98	5.9k
Susan L. Holbeck United States	29	1.9k 0.8×	536 0.5×	264 0.3×	361 0.7×	551 2.1×	54	3.1k
Enrico Pesenti Italy	28	1.3k 0.6×	1.0k 0.9×	250 0.3×	87 0.2×	362 1.4×	67	2.7k
Marc R. Birtwistle United States	23	1.8k 0.8×	400 0.4×	89 0.1×	260 0.5×	231 0.9×	74	2.5k
Omar D. Perez United States	22	2.2k 0.9×	502 0.5×	204 0.3×	185 0.4×	255 1.0×	28	3.7k
Laura M. Heiser United States	25	972 0.4×	501 0.5×	130 0.2×	160 0.3×	357 1.4×	69	2.2k

Countries citing papers authored by Birgit Schoeberl

Since Specialization

Citations

This map shows the geographic impact of Birgit Schoeberl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgit Schoeberl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgit Schoeberl more than expected).

Fields of papers citing papers by Birgit Schoeberl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgit Schoeberl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgit Schoeberl. The network helps show where Birgit Schoeberl may publish in the future.

Co-authorship network of co-authors of Birgit Schoeberl

This figure shows the co-authorship network connecting the top 25 collaborators of Birgit Schoeberl. A scholar is included among the top collaborators of Birgit Schoeberl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgit Schoeberl. Birgit Schoeberl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abla, Nada, et al.. (2025). Physiologically based pharmacokinetic modelling to predict artemether and lumefantrine exposure in neonates weighing less than 5 kg treated with artemether–lumefantrine to supplement the clinical data from the CALINA study. Tropical Medicine and Health. 53(1). 116–116.

Tata, Rolland Bantar, et al.. (2023). Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles. International Journal of Molecular Sciences. 24(4). 3383–3383. 13 indexed citations

Ferrero, Enrico, Sophie Brachat, Jeremy L. Jenkins, et al.. (2020). Ten simple rules to power drug discovery with data science. PLoS Computational Biology. 16(8). e1008126–e1008126. 10 indexed citations

Schoeberl, Birgit. (2019). Quantitative Systems Pharmacology models as a key to translational medicine. Current Opinion in Systems Biology. 16. 25–31. 5 indexed citations

Pace, Emily A., Sharlene Adams, Michael D. Curley, et al.. (2018). Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research. 24(12). 2873–2885. 44 indexed citations

Alkan, Ozan, Birgit Schoeberl, Alexander Koshkaryev, et al.. (2018). Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway. Science Signaling. 11(540). 19 indexed citations

Kirouac, Daniel C., Jinyan Du, Johanna Lahdenranta, et al.. (2016). HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. PLoS Computational Biology. 12(4). e1004827–e1004827. 32 indexed citations

Abu‐Yousif, Adnan O., Jessica B. Casaletto, Kristina Masson, et al.. (2015). Abstract 1690: Mechanistic characterization of MM-131, a bispecific antibody that blocks c-Met signaling through concurrent targeting of EpCAM. Cancer Research. 75(15_Supplement). 1690–1690. 2 indexed citations

Niepel, Mario, Marc Hafner, Emily A. Pace, et al.. (2014). Analysis of growth factor signaling in genetically diverse breast cancer lines. BMC Biology. 12(1). 20–20. 32 indexed citations

10.

Fitzgerald, Jonathan B., Bryan W. Johnson, Jason Baum, et al.. (2013). MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors. Molecular Cancer Therapeutics. 13(2). 410–425. 87 indexed citations

11.

Kopesky, Paul W., et al.. (2013). Dexamethasone can rescue cytokine-induced chondrocyte apoptosis in bovine and human cartilage. Osteoarthritis and Cartilage. 21. S40–S41. 2 indexed citations

12.

Zhou, Yu, Brian D. Harms, Hao Zou, et al.. (2012). Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies. Molecular Cancer Therapeutics. 11(7). 1467–1476. 54 indexed citations

13.

McDonagh, Charlotte F., Alexandra Huhalov, Brian D. Harms, et al.. (2012). Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3. Molecular Cancer Therapeutics. 11(3). 582–593. 222 indexed citations

14.

Baum, Jason, Bryan W. Johnson, Sharlene Adams, et al.. (2012). Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity. Cancer Research. 72(8_Supplement). 2719–2719. 3 indexed citations

15.

Harms, Brian D., Jeffrey D. Kearns, Stephen Su, et al.. (2011). Optimizing Properties of Antireceptor Antibodies Using Kinetic Computational Models and Experiments. Methods in enzymology on CD-ROM/Methods in enzymology. 502. 67–87. 22 indexed citations

16.

Schoeberl, Birgit, Anthony C. Faber, Danan Li, et al.. (2010). An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation. Cancer Research. 70(6). 2485–2494. 215 indexed citations

17.

Sheng, Qing, Xinggang Liu, Eleanor Fleming, et al.. (2010). An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. Cancer Cell. 17(3). 298–310. 178 indexed citations

18.

Chen, William W., Birgit Schoeberl, Paul Jasper, et al.. (2009). Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Molecular Systems Biology. 5(1). 239–239. 276 indexed citations

19.

Fitzgerald, Jonathan B., Birgit Schoeberl, Ulrik B. Nielsen, & Peter K. Sorger. (2006). Systems biology and combination therapy in the quest for clinical efficacy. Nature Chemical Biology. 2(9). 458–466. 439 indexed citations

20.

Schoeberl, Birgit, et al.. (2006). A Data-Driven Computational Model of the ErbB Receptor Signaling Network. PubMed. 8. 53–54. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact